Enterprise value of players in oncology rare disease therapeutics 2017

This statistic shows the enterprise value of leading pure players in rare oncology disease therapeutics worldwide as of 2017. As of that year, the value of Celgene which is specialized on multiple meloma therapeutics was around 113 billion U.S. dollars.

Enterprise value of leading pure players in oncology rare disease therapeutics worldwide as of 2017 (in million U.S. dollars)*

Value in million U.S. dollars
Celgene113,055
Incyte23,576
Genmab13,477
Kite Pharma9,533
Exellxis7,773
Seattle Genetics7,207
Tesaro6,122
Juno Therapeutics4,182
Clovis Oncology3,735
Array Biopharma2,307
Loxo Oncology2,149
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

2017

Region

Worldwide

Survey time period

as of October 2017

Method of interview

Online survey

Supplementary notes

* All values are in current U.S. dollars.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.